CoChat

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease

Open access

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Abstract

Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awab223

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Plasma and CSF GFAP concentrations are increased in amyloid-β-positive groups. Violin plots with median values for plasma and CSF GFAP (z-scores) in amyloid-β-negative cognitively unimpaired individuals (CU Aβ−), amyloid-β-positive cognitively unimpaired individuals (CU Aβ+), amyloid-β-positive cognitively impaired individuals (CI Aβ+), amyloid-β-negative cognitively impaired individuals (CI Aβ−) and non-Alzheimer’s disease disorders, after adjusting for age and sex. *Significant group differences after adjusting for multiple comparisons with FDR corrections (q < 0.05).
Figure 1 Plasma and CSF GFAP concentrations are increased in amyloid-β-positive groups. Violin plots with median values for plasma and CSF GFAP (z-scores) in amyloid-β-negative cognitively unimpaired individuals (CU Aβ−), amyloid-β-positive cognitively unimpaired individuals (CU Aβ+), amyloid-β-positive cognitively impaired individuals (CI Aβ+), amyloid-β-negative cognitively impaired individuals (CI Aβ−) and non-Alzheimer’s disease disorders, after adjusting for age and sex. *Significant group differences after adjusting for multiple comparisons with FDR corrections (q < 0.05).CC BY-NC · PubMed Central
Figure 2 Plasma and CSF GFAP concentrations are associated with amyloid-β-PET independently of tau-PET burden. Results of the linear regression analyses showing a significant relationship between amyloid-β burden measured on PET (Aβ-PET) (z-scores) and plasma GFAP (z-scores) in (A) all cognitively unimpaired individuals (CU), (B) amyloid-β-negative cognitively unimpaired individuals (CU Aβ−), (C) amyloid-β-positive cognitively unimpaired individuals (CU Aβ+), and (D) amyloid-β-positive cognitively impaired individuals (CI Aβ+), after adjusting for age and sex. In addition, a significant relationship between amyloid-β-PET and CSF GFAP (z-scores) was also found in (E) amyloid-β-positive cognitively unimpaired individuals (CU Aβ+). The top panel shows correlation plots between amyloid-β-PET and GFAP markers, whereas the bottom panel shows box plots depicting how amyloid-β-PET values vary according to GFAP quartiles. All associations remained significant after controlling for tau-PET burden.
Figure 2 Plasma and CSF GFAP concentrations are associated with amyloid-β-PET independently of tau-PET burden. Results of the linear regression analyses showing a significant relationship between amyloid-β burden measured on PET (Aβ-PET) (z-scores) and plasma GFAP (z-scores) in (A) all cognitively unimpaired individuals (CU), (B) amyloid-β-negative cognitively unimpaired individuals (CU Aβ−), (C) amyloid-β-positive cognitively unimpaired individuals (CU Aβ+), and (D) amyloid-β-positive cognitively impaired individuals (CI Aβ+), after adjusting for age and sex. In addition, a significant relationship between amyloid-β-PET and CSF GFAP (z-scores) was also found in (E) amyloid-β-positive cognitively unimpaired individuals (CU Aβ+). The top panel shows correlation plots between amyloid-β-PET and GFAP markers, whereas the bottom panel shows box plots depicting how amyloid-β-PET values vary according to GFAP quartiles. All associations remained significant after controlling for tau-PET burden.CC BY-NC · PubMed Central
Figure 3 Voxel-wise associations between plasma GFAP and amyloid-β-PET. Results of the voxel-wise regression analyses showing a significant relationship between amyloid-β burden measured on PET images and plasma GFAP in (A) all cognitively unimpaired individuals (CU) and (B) amyloid-β-positive cognitively unimpaired individuals (CU Aβ+), and (D) amyloid-β-positive cognitively impaired individuals (CI Aβ+), after adjusting for age and sex. All results were adjusted for multiple comparisons using FDR (q < 0.05).
Figure 3 Voxel-wise associations between plasma GFAP and amyloid-β-PET. Results of the voxel-wise regression analyses showing a significant relationship between amyloid-β burden measured on PET images and plasma GFAP in (A) all cognitively unimpaired individuals (CU) and (B) amyloid-β-positive cognitively unimpaired individuals (CU Aβ+), and (D) amyloid-β-positive cognitively impaired individuals (CI Aβ+), after adjusting for age and sex. All results were adjusted for multiple comparisons using FDR (q < 0.05).CC BY-NC · PubMed Central
Figure 4 Plasma GFAP shows early increases with amyloid-β-PET burden. Spline models showing the trajectories for (A) plasma GFAP and (B) CSF GFAP using global amyloid-β-PET SUVR as a proxy for time. Both models were significant; however, when the splines of plasma and CSF GFAP were compared, plasma GFAP showed steeper initial increases, overcoming CSF GFAP levels even before amyloid-β-PET positivity (C). Aβ = amyloid-β.
Figure 4 Plasma GFAP shows early increases with amyloid-β-PET burden. Spline models showing the trajectories for (A) plasma GFAP and (B) CSF GFAP using global amyloid-β-PET SUVR as a proxy for time. Both models were significant; however, when the splines of plasma and CSF GFAP were compared, plasma GFAP showed steeper initial increases, overcoming CSF GFAP levels even before amyloid-β-PET positivity (C). Aβ = amyloid-β.CC BY-NC · PubMed Central
Figure 5 Plasma GFAP has a greater diagnostic accuracy in identifying an amyloid-β-positive status compared to other glial markers. Results of the receiver-operating curve analyses showing that plasma GFAP showed a better classification performance in distinguishing amyloid-β-PET-positive from amyloid-β-PET-negative individuals in (A) the whole sample, (B) all cognitively unimpaired individuals (CU) and (C) all amyloid-β-positive cognitively impaired individuals (CI). Moreover, plasma GFAP also showed a better classification performance in distinguishing patients with abnormal and normal CSF amyloid-β42/40 levels in a group of patients with non-Alzheimer’s disease disorders (D). AD = Alzheimer's disease; AUC = area under the curve.
Figure 5 Plasma GFAP has a greater diagnostic accuracy in identifying an amyloid-β-positive status compared to other glial markers. Results of the receiver-operating curve analyses showing that plasma GFAP showed a better classification performance in distinguishing amyloid-β-PET-positive from amyloid-β-PET-negative individuals in (A) the whole sample, (B) all cognitively unimpaired individuals (CU) and (C) all amyloid-β-positive cognitively impaired individuals (CI). Moreover, plasma GFAP also showed a better classification performance in distinguishing patients with abnormal and normal CSF amyloid-β42/40 levels in a group of patients with non-Alzheimer’s disease disorders (D). AD = Alzheimer's disease; AUC = area under the curve.CC BY-NC · PubMed Central
Figure 6 Relationship between plasma and CSF GFAP with longitudinal amyloid-β accumulation and cognitive decline. Predicted trajectories for longitudinal amyloid-β (Aβ) accumulation determined by PET and MMSE scores (z-scores) in relation to plasma and CSF GFAP in the whole sample, after adjusting for covariates. The models were fit using continuous GFAP values but for illustration purposes the plots show the trajectories for individuals with high and low plasma GFAP for longitudinal amyloid-β-PET (A) and longitudinal MMSE (B) as well as for individuals with high and low CSF GFAP for longitudinal MMSE (C). All results were adjusted for multiple comparisons using FDR (q < 0.05).
Figure 6 Relationship between plasma and CSF GFAP with longitudinal amyloid-β accumulation and cognitive decline. Predicted trajectories for longitudinal amyloid-β (Aβ) accumulation determined by PET and MMSE scores (z-scores) in relation to plasma and CSF GFAP in the whole sample, after adjusting for covariates. The models were fit using continuous GFAP values but for illustration purposes the plots show the trajectories for individuals with high and low plasma GFAP for longitudinal amyloid-β-PET (A) and longitudinal MMSE (B) as well as for individuals with high and low CSF GFAP for longitudinal MMSE (C). All results were adjusted for multiple comparisons using FDR (q < 0.05).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page

Cited by

See all 660

Metadata

Authors
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
Affiliations
  • Lund University (SE)
  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
  • Amsterdam Neuroscience (NL)
  • Sahlgrenska University Hospital (SE)
  • King's College London (GB)
Corresponding author
  • Pereira, Joana B
  • Hansson, Oskar
Venue
Brain
Published
2021-07-02
Volume
144
Issue
11
Pages
3505-3516
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W3182927843
Cited by
598
References
61
Citations by year
2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
FWCI
48.47
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
  • Knut and Alice Wallenberg foundation (2017–0383)
  • Marianne and Marcus Wallenberg foundation (2015.0125)
  • Strategic Research Area MultiPark
  • Swedish Alzheimer Foundation (AF-939932, #AF-742881)
  • Swedish Brain Foundation (FO2019-0326)
  • The Parkinson foundation of Sweden (1280/20)
  • Skåne University Hospital Foundation (2020-O000028)
  • Regionalt Forskningsstöd (2020–0314)
  • Swedish federal government (2018-Projekt0279)
  • The Center for Medical Innovation (#20200695)
  • Karolinska Institute
  • Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
  • Hjärnfonden, Sweden (#FO2017-0243)
  • ALF (#ALFGBG-715986)
  • European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
  • European Research Council (#681712)
  • Swedish State Support for Clinical Research (#ALFGBG-720931)
  • UK Dementia Research Institute
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
MeSH terms
Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.